Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

Bengt I. Eriksson; Ola E. Dahl; Michael H. Huo; Andreas A. Kurth; Stefan Hantel; Karin Hermansson; Janet M. Schnee; Richard J. Friedman; for the RE-NOVATE II Study Group

doi:10.1160/TH10-10-0679

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(04): 721-729
DOI: 10.1160/TH10-10-0679

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II^[*])

A randomised, double-blind, non-inferiority trial

Authors

Bengt I. Eriksson

¹University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden
Ola E. Dahl

²Elverum Central Hospital, Norway; Thrombosis Research Institute, London, United Kingdom
Michael H. Huo

³Department of Orthopedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Andreas A. Kurth

⁴Department of Orthopaedic Surgery, University Medical Centre, Mainz, Germany
Stefan Hantel

⁵Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
Karin Hermansson

⁶Medical Department, Boehringer Ingelheim AB, Stockholm, Sweden
Janet M. Schnee

⁷Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA
Richard J. Friedman

⁸Medical University of South Carolina and Charleston Orthopaedic Associates, Charleston, South Carolina, USA

for the RE-NOVATE II Study Group

Abstract

Summary

This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embolism) plus VTE-related death. The main safety outcome was major bleeding. In total, 2,013 were treated, of whom 1,577 operated patients were included in the primary efficacy analysis. The primary efficacy outcome occurred in 7.7% of the dabigatran group versus 8.8% of the enoxaparin group, risk difference (RD) –1.1% (95%CI –3.8 to 1.6%); p<0.0001 for the pre-specified non-inferiority margin. Major VTE plus VTE-related death occurred in 2.2% of the dabigatran group versus 4.2% of the enoxaparin group, RD –1.9% (-3.6% to –0.2%); p=0.03. Major bleeding occurred in 1.4% of the dabigatran group and 0.9% of the enoxaparin group (p=0.40). The incidence of adverse events, including liver enzyme elevations and cardiac events, during treatment was similar between the groups. Extended prophylaxis with oral dabigatran 220 mg once-daily was as effective as sub-cutaneous enoxaparin 40 mg once-daily in reducing the risk of VTE after total hip arthroplasty, and superior to enoxaparin for reducing the risk of major VTE. The risk of bleeding and safety profiles were similar.

Keywords

Dabigatran etexilate - oral anticoagulant - total hip arthroplasty - prophylaxis - venous thromboembolism

Full Text

References

References
1 Friedman RJ, Gallus AS, Cushner FD. et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008; 24: 87-97.
2 Sweetland S, Green J, Liu B. et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. Br Med J 2009; 339: b4583. prepublished online doi:10.1136/bmj.b4583.
3 Geerts WH, Pineo GF, Heit JA. et al. Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl 338S-400S.
4 Warwick D, Friedman RJ, Agnelli G. et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
5 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
6 Health Canada, Register of Innovative Drugs. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/reg_innov_dr-eng.php Accessed Jan 13, 2010.
7 European Medicines Agency.. Pradaxa. Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf Accessed Dec 1, 2010.
8 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
9 RE-MOBILIZE Writing Committee. Ginsberg JS, Davidson BL, Comp PC. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
10 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
11 Kälebo P, Anthmyr BA, Eriksson BI. et al. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiologica 1997; 38: 320-326.
12 The European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use (CHMP).. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. Available at http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf Accessed Dec 1, 2009.
13 Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am 1969; 51: 737-755.
14 Eriksson BI, Agnelli G, Cohen AT. et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288-296.
15 Eriksson BI, Agnelli G, Cohen AT. et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-2496.
16 Eriksson BI, Dahl OE, Buller HR. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111.
17 Turpie AG, Levine MN, Hirsh J. et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.
18 Kalodiki EP, Hoppensteadt DA, Nicolaides AN. et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol 1996; 15: 162-168.
19 Samama CM, Clergue F, Barre J. et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth 1997; 78: 660-665.
20 FDA.. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm Accessed Apr 1, 2010.
21 Lassen MR, Bauer KA, Eriksson BI. et al. Postoperative fondaparinux versus pre-operative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
22 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
23 Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-1342.
24 Jameson SS, Bottle A, Malviya A. et al. The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb. J Bone Joint Surg Br 2010; 92: 123-129.
25 Connolly SJ, Ezekowitz MD, Yusuf S. et al. RE-LY Steering Committee and Investigators.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
26 Schulman S, Kearon C, Kakkar AK. et al. the RE-COVER Study Group.. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
27 Stangier J, Eriksson BI, Dahl OE. et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563.
28 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II[*])

Authors

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II^[*])